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Abstract
Background: ErbB2-positive breast cancer is characterized by highly aggressive phenotypes and reduced
responsiveness to standard therapies. Although specific ErbB2-targeted therapies have been designed, only a small
percentage of patients respond to these treatments and most of them eventually relapse. The existence of this
population of particularly aggressive and non-responding or relapsing patients urges the search for novel therapies.
The purpose of this study was to determine whether cannabinoids might constitute a new therapeutic tool for the
treatment of ErbB2-positive breast tumors. We analyzed their antitumor potential in a well established and clinically
relevant model of ErbB2-driven metastatic breast cancer: the MMTV-neu mouse. We also analyzed the expression of
cannabinoid targets in a series of 87 human breast tumors.
Results: Our results show that both Δ9-tetrahydrocannabinol, the most abundant and potent cannabinoid in
marijuana, and JWH-133, a non-psychotropic CB2 receptor-selective agonist, reduce tumor growth, tumor number,
and the amount/severity of lung metastases in MMTV-neu mice. Histological analyses of the tumors revealed that
cannabinoids inhibit cancer cell proliferation, induce cancer cell apoptosis, and impair tumor angiogenesis.
Cannabinoid antitumoral action relies, at least partially, on the inhibition of the pro-tumorigenic Akt pathway. We
also found that 91% of ErbB2-positive tumors express the non-psychotropic cannabinoid receptor CB2.
Conclusions: Taken together, these results provide a strong preclinical evidence for the use of cannabinoid-based
therapies for the management of ErbB2-positive breast cancer.
Background
Breast cancer represents approximately 30% of newly
diagnosed cancers each year. Almost one third of them
overexpresses the ErbB2 tyrosine kinase receptor (Her2
in humans, Neu in rats), a member of the EGF receptor
family [1]. Phosphorylation of their intracellular domains
upon engagement by their ligands induce receptor
homo- or heterodimerization, leading to the activation
of key signaling pathways that promote cell proliferation
and survival, including the phosphatidylinositol 3-kinase
(PI3K)/Akt pathway and the ERK/MAPK cascade.
Although no specific ligand for ErbB2 has been identi-
fied yet, this receptor is the preferred heterodimerization
partner of the family [2]. ErbB2-overexpressing breast
tumors are characterized by very aggressive clinical
courses and decreased survival rates, mostly due to the
poorly differentiated, highly proliferative and highly
invasive nature of their constituent cells [2]. All these
characteristics make ErbB2-overexpressing tumors less
responsive to conventional therapies. One of the most
recent advances in the treatment of these tumors is the
use of a humanized neutralizing monoclonal antibody
against ErbB2 (Trastuzumab) [3]. Although this strategy
has been very successful, around 75% of patients with
ErbB2-overexpressing tumors do not respond to Trastu-
zumab, and nearly 15% of the responders eventually
develop metastases [4]. The existence of this consider-
able population of non-responding and relapsing
patients urges the search for novel treatments.
The therapeutic potential of cannabinoids, the active
compounds of marijuana and their derivatives, has been
known for centuries. There is increasing evidence sup-
porting that they might be beneficial in various patholo-
gical contexts such as pain, inflammation, eating
disorders, and brain damage, amongst others [5,6].
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Cannabinoids exert most of their actions by binding to
and activating specific G protein-coupled receptors. To
date, two cannabinoid receptors, namely CB1 and CB2,
have been cloned and characterized from mammalian
tissues, the main difference between them being their
tissue expression pattern. Thus, while CB1 receptors are
ubiquitously located, with their highest presence found
in the central nervous system, CB2 receptor expression
is mostly restricted to particular elements of the
immune system [5,6]. During the last decade, evidence
has accumulated suggesting that cannabinoids might be
useful for the treatment of cancer. These compounds
exert anti-proliferative, pro-apoptotic, anti-angiogenic,
and anti-invasive effects in different cell-culture and ani-
mal models of cancer [7,8]. Here, we used a genetically
engineered animal model of ErbB2-driven metastatic
breast cancer (the MMTV-neu mouse) to analyze the
antitumoral potential of cannabinoids in this particularly
aggressive pathology. These animals express the rat
ErbB2 oncogene (neu) under the control of the hor-
mone-sensitive mouse mammary tumor virus-long term-
inal repeat (MMTV-LTR) promoter [9]. Selective
overexpression of neu in the mammary epithelium
results in the spontaneous development of focal mam-
mary tumors after a long latency (5-12 months) [9].
Results presented herein (i) show that ErbB2-positive
invasive human breast tumors express CB2 receptors, (ii)
demonstrate that Δ9-tetrahydrocannabinol (THC) and
the non-psychotropic CB2 cannabinoid receptor agonist
JWH-133 significantly reduce tumor progression in a
clinically relevant model of ErbB2-positive metastatic
breast cancer, and (iii) shed light on the mechanism of
cannabinoid antitumoral action in vivo.
Results
Human ErbB2-positive breast tumors express CB2
cannabinoid receptors
We first analyzed whether ErbB2-positive human breast
tumors express cannabinoid targets (i.e. cannabinoid
receptors). We performed an immunohistochemical ana-
lysis of CB1 and CB2 receptors in 87 grade 3 invasive
breast ductal carcinomas and 6 non-tumoral mammary
samples by tissue microarrays. CB1 immunoreactivity
was detected in only 14% of the tumors (12/87), and no
correlation was found between this receptor expression
and ErbB2 expression (p = 0.198, Fig. 1). Conversely,
CB2 receptor staining was evident in 72% of the carcino-
mas (63/87) and it was significantly associated with
ErbB2 expression, since it was observed in 91% of the
ErbB2-positive tumors (21/23, p = 0.018, Fig. 1). More-
over, we detected no significant CB1 or CB2 receptor
immunoreactivity in non-transformed mammary tissue
(data not shown).
Cannabinoids exert an antitumoral effect in the MMTV-
neu model of breast cancer
We then analyzed the effect of cannabinoids on tumor
progression in a well established and clinically relevant
animal model of ErbB2-driven metastatic breast cancer,
the MMTV-neu mouse. We first observed that our
MMTV-neu colony develops breast tumors after a long
latency period similar to that previously reported [9]. In
particular, 50% of the females had tumors by week 36
(Additional file 1: Fig. S1A). Overexpression of the rat
ErbB2 transgene (neu) in the tumors was verified by
real-time quantitative PCR (Additional file 1: Fig. S1B).
Treatment with cannabinoids, either THC, the main
marijuana-derived cannabinoid in terms of abundance
and potency, or JWH-133, a synthetic CB2 receptor-
selective agonist, strongly slowed down tumor growth
(Fig. 2A), leading to smaller lesions at the end of the
treatment (Additional file 1: Fig. S2). These compounds,
however, did not change the histomorphologic features
of the tumors. Thus, the three different experimental
groups generated focal, ductal, solid, well vascularized
mammary tumors surrounded by a non-invasive
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Figure 1 ErbB2-positive human breast tumors express
cannabinoid receptors. (A) Representative images of human breast
tumors negative (upper row) or positive (lower row) for CB1, CB2
and ErbB2 receptors (brown). Scale bars: 200 μm; insets: 100 μm. (B)
Percentage of tumors scored as positive or negative for
cannabinoid receptor expression amongst the ErbB2-negative (n =
64) and ErbB2-positive (n = 23) populations.
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hyperplasic mammary epithelium (Fig. 2B). We also
observed that MMTV-neu-derived tumors express CB1
and CB2 cannabinoid receptor mRNA (determined by
real-time quantitative PCR, data not shown) and protein
(Additional file 1: Fig. S3).
Of interest, cannabinoids not only impaired tumor
growth, but also blocked tumor generation per se. Thus,
while 41% of vehicle-treated animals developed 4 or
more tumors (up to 6), cannabinoid-treated animals
never developed more than 3 tumors (Fig. 2C, p < 0.05).
Consequently, total tumor burden was strikingly
decreased by cannabinoids (Fig. 2D). There was also a
delay in the appearance of the subsequent tumors in
these animals. Thus, the average latency for the genera-
tion of a second tumor in vehicle-treated, THC-treated
and JWH-133-treated animals was 33, 46 and 54 days,
respectively. As mentioned in the Methods section, only
the first tumor in each animal was treated peritumorally
with cannabinoids. However, we detected a remarkable
growth-inhibitory effect of cannabinoids in those tumors
appeared in second place (Fig. 2E).
Cannabinoids impact tumor cell proliferation, tumor cell
survival and tumor angiogenesis
We next analyzed the proliferative potential of cancer
cells and found that it was reduced by both THC and
JWH-133, as indicated by a decreased number of Ki67-
positive cells in cannabinoid-treated tumors (Fig. 3A).
Cannabinoid administration also increased the number
of cleaved (active) caspase 3-positive cells within the
tumors, indicating that these compounds induce cancer
cell death by apoptosis (Fig. 3B). Tumor vascularization
was also impaired by cannabinoids, as both THC and
JWH-133 decreased the number of blood vessels in the
tumors, as determined by CD31 staining (Fig. 3C). To
evaluate the possible contribution of the immune
response to cannabinoid antitumoral action, we analyzed
by immunofluorescence the degree of immune infiltra-
tion in the tumors. The percentage of CD45-positive
cells (differentiated hematopoietic cells except erythro-
cytes and platelets) within the tumors was very low in
all the samples tested and no significant differences
between experimental groups were detected (Fig. 3D).
These data suggest that cannabinoid treatment does not
affect the infiltration of immune cells into the tumor
parenchyma.
Cannabinoids decrease breast cancer metastases in the
lungs
It has been previously reported that a high percentage of
tumor-bearing MMTV-neu animals develop metastases
in the lungs [9]. Specifically, we detected lung metas-
tases (Fig. 4A) in 67% of our vehicle-treated MMTV-
neu animals (Fig. 4B). The cell morphology, tumor
architecture, and overexpression of the neu transgene
mRNA in these lung structures confirmed the metastatic
nature of the lesions (Figs. S1C and D). THC reduced
the percentage of animals with lung metastases (Fig.
4B). Although JWH-133 did not decrease this propor-
tion, it significantly reduced the magnitude of the
lesions. Thus, half of the metastases in this experimental
group were detectable only by microscopic analysis (Fig.
4B). As it was observed for the primary breast tumors,
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Figure 2 Cannabinoids inhibit breast tumor growth in vivo and
the number of tumors generated per animal. (A) Volume time-
course (scale bar: 1 cm) of the first tumor appeared in each animal.
(B) Representative images (H&E staining) of the histopathology of
the MMTV-neu-derived mammary tumors. Scale bars (from left to
right): 200 μm, 100 μm and 50 μm. (C) Percentage of animals with
1, 2, 3, 4 or more tumors at the end of the treatment (90 days) in
each experimental group. (D) Total tumor burden (total tumor
volume per animal) determined 90 days after cannabinoid or
vehicle treatment. (E) Volume of the tumors appeared in second,
third or subsequent positions, 40 days after their appearance. The
small size of the cannabinoid-treated groups is due to the very few
second or third tumors appeared early enough to last 40 days in
the animals before the end of the treatment (90 days after the
appearance of the first tumor).
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cannabinoid treatment did not alter the histopathology
of the metastases, and the three experimental groups
presented similar solid adenocarcinomas (Additional file
1: Fig. S1C). No sign of metastasis was detected in any
of the other organs analyzed (brain, spleen, liver, kidneys
-by histological analysis- and bones -by X-rays) in any of
the experimental groups (data not shown).
Degradation of the extracellular matrix is a crucial step
in the metastatic process, especially during tumor cell
intravasation and extravasation [10]. Matrix metallopro-
teinases (MMPs) have long been associated with this pro-
cess owing to their ability to degrade the components of
the extracellular matrix. To analyze whether cannabinoid
administration affects MMP activity we conducted gela-
tin zymographies. MMP2 activity was decreased in THC-
and JWH-133-treated tumors, while MMP9 activity was
enhanced by cannabinoid treatment (Fig. 4C). This THC-
and JWH-133-induced reduction in MMP2 activity was
accompanied by a decrease in MMP2 mRNA levels
(Additional file 1: Fig. S4A). Conversely, cannabinoids
did not change the amount of MMP9 transcripts (Addi-
tional file 1: Fig. S4A) and enhanced its protein levels
(Additional file 1: Fig. S4B), indicating that they regulate
MMP9 post-transcriptionally.
Akt downregulation is involved in cannabinoid
antitumoral action
We next aimed at characterizing the mechanism under-
lying cannabinoid antitumoral effect. It is well estab-
lished that several types of human cancers are
associated with deregulation of signaling via ErbB
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Figure 3 Cannabinoids inhibit cancer cell proliferation, induce
cancer cell apoptosis, and impair tumor angiogenesis in vivo.
(A) Ki67-positive cells (red), (B) active caspase-3-positive cells (red),
(C) CD31-positive cells (green) and (D) CD45-positive area in the
tumors. Scale bars: A, 60 μm; B, 40 μm; C and D, 100 μm. Cell nuclei
are in blue. Quantifications of Ki67-positive cells (A), active caspase-
3-positive cells (B), the number of blood vessels (C) and CD45-
positive area (D) in the tumors are shown in the corresponding
graphs.
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Figure 4 Cannabinoids inhibit breast cancer metastasis to the
lungs in vivo. (A) Metastatic lung nodules (pointed by arrows). (B)
Percentage of animals with lung metastases. Macroscopic
metastases were visible to the naked eye and microscopic lesions
were detectable only by H&E staining. These latter lesions were
found only in JWH-133-treated animals. (C) Gelatin zymographies of
vehicle- and cannabinoid-treated tumors. Four representative
tumors are shown per experimental group. PC: positive control
(conditioned medium of H71080 cells stimulated with the phorbol
ester PMA). Arrows point to the latent (pro-MMP) and active MMP
bands according to the positive control and the expected MMP
molecular weights. Non-contiguous parts of the same gel are
shown. Graphs show the densitometric analysis of MMP2 and
MMP9 activities. Data are expressed in arbitrary units. *, p < 0.05 vs
vehicle-treated tumors; §, p = 0.068 vs vehicle-treated tumors.
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members [1]. In particular, ErbB2 overexpression corre-
lates, for instance, with tumor size, increased metastatic
potential, and higher histological grade, implying that
ErbB2 confers a strong proliferative and survival advan-
tage to tumor cells [11]. To assess whether cannabinoids
modulate the expression of endogenous ErbB2 and of
the rat ErbB2 ortologue neu, which is ectopically
expressed in our animal model, we conducted real-time
quantitative PCR determinations upon THC and JWH-
133 treatment. However, no significant changes were
detected (Fig. 5A).
A central intracellular signaling pathway activated by
ErbB2 is the PI3K/Akt pathway, whose importance in
breast cancer is corroborated by clinical studies showing
Akt activation in most ErbB2-overexpressing tumors
[11]. We observed a decrease in Akt activation in THC-
treated MMTV-neu tumors (Fig. 5B) as well as dimin-
ished levels of phosphorylated S6 ribosomal protein [a
read-out for activation of the Akt/mammalian target of
rapamycin (mTOR) pathway [12]] (Fig. 5C). To
determine the importance of Akt inhibition in cannabi-
noid antitumoral action we conducted different experi-
ments with the cell line N202.1A, that was isolated from
a MMTV-neu breast tumor [13]. THC and JWH-133
decreased N202.1A cell proliferation (Fig. 6A) in a
CB2 receptor-dependent manner, as indicated by the
prevention of cannabinoid action exerted by the CB2
receptor-selective antagonist SR144528 but not by the
CB1 receptor-selective antagonist SR141716 (Fig. 6B).
Likewise, the growth rate of N202.1A-derived xenografts
was significantly diminished by THC and JWH-133, and
this effect was prevented by SR144528 (Fig. 6C). THC
also decreased cell proliferation of two different ErbB2-
overexpressing breast cancer cell lines of human origin
(Additional file 1: Fig. S5), suggesting that human
ErbB2-positive breast tumor cells may be sensitive to
cannabinoid antitumoral action as well. N202.1A cells
showed a dose-dependent reduction in Akt activation
(Fig. 6D). Of interest, overexpression of a myristoylated
(i.e. constitutively activated) form of Akt (Fig. 6E) pre-
vented THC antiproliferative effect (Fig. 6F). To further
support the importance of Akt in cannabinoid antitu-
moral action, subcutaneous xenografts were generated
in nude mice with N202.1A cells stably expressing myr-
istoylated Akt or the corresponding empty vector
(pBABE). As shown in Fig. 6G (left panel), THC signifi-
cantly reduced the growth of pBABE-transfected
N202.1A-derived tumors. In contrast, overexpression of
activated Akt prevented THC effect on tumor progres-
sion (Fig. 6G, right panel). The same effect was observed
with JWH-133 (Fig. 6H).
Discussion
Aberrant ErbB2 expression and/or function yield highly
aggressive tumors, with increased resistance to conven-
tional chemotherapies and poor outcomes. Although the
use of the anti-ErbB2 monoclonal antibody Trastuzu-
mab markedly improves the survival of these patients,
only 25% of them respond to this treatment and most of
the responders eventually relapse [14]. Moreover, the
use of this antibody has been associated with important
cardiotoxic side effects (severe congestive heart failure
and decrease in left ventricular ejection fraction) [14].
Consequently, extensive efforts should be made to find
novel agents for the treatment of ErbB2-positive breast
tumors. Our results demonstrate that, in spontaneously
aroused ErbB2-overexpressing breast tumors, cannabi-
noids inhibit tumor generation, growth, vascularization,
and metastasis. Although a cannabinoid-based mono-
therapy might be potentially effective for ErbB2-positive
breast tumors, it would be interesting to analyze the
effect of these compounds in combination with other
anticancer treatments. Thus, it is worth noting that
Trastuzumab, the most relevant targeted therapy for
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ErbB2-positive tumors so far, has a modest median
overall response when used as a first-line agent, an effi-
cacy that is clearly enhanced when used in combination
with other chemotherapeutic agents [14]. Additionally,
Akt overactivation has been detected in a significant
percentage of primary human breast cancers, in which it
is associated to enhanced resistance to Trastuzumab
[14,15]. Our results show that downregulation of Akt is
involved in cannabinoid antitumoral action. This kinase
is the central node of the PI3K/Akt/mTOR signaling
pathway, that activates crucial processes such as cell
survival, cell growth, cell proliferation, angiogenesis, and
cell migration and invasion [12]. This pathway is there-
fore an attractive target for anticancer agents and, as a
matter of fact, clinical trials have been/are being con-
ducted with mTOR, PI3K and Akt inhibitors [3].
The antitumoral potential of cannabinoids has been
documented both in vitro and in animal models of can-
cer [7,8]. These compounds inhibit breast cancer cell
proliferation in vitro through processes that include cell
cycle arrest [16-21], hormone and growth-factor recep-
tor modulation [18,22,23], and apoptosis induction
[17,20,21]. The in vivo approaches followed so far have
been mostly based on xenograft models [20,21], which
are helpful but limited tools. These models rely on the
propagation of cancer cell lines in immunodeficient
mice at ectopic or orthotopic sites and lack crucial fea-
tures of patients’ tumors such as the actual tumor archi-
tecture and the interactions with the tumor
microenvironment (including non-cancerous surround-
ing tissue, vasculature and immune cells) and dimin-
ished genetic heterogeneity [24]. In contrast to
xenografted animals, in the mutant mice used in this
study tumors appear spontaneously and after long
latency periods, recruit and generate blood vessels, and
penetrate the vasculature giving rise to distant metas-
tases [9]. These features parallel the human pathology
much more closely and make the MMTV-neu mice a
clinically relevant model of ErbB2-driven breast cancer.
Remarkably, this is, to the best of our knowledge, the
first report supporting that cannabinoids hamper not
only tumor growth but also tumor generation. Recently,
Qamri and coworkers and DuBois and coworkers, by
using two different genetic models of cancer, demon-
strated that JWH-133 delays the appearance of breast
tumors [21] and that the loss of CB1 receptors accelerates
intestinal adenoma growth [25], respectively, and Izzo
et al. observed that high endocannabinoid levels and the
cannabinoid agonist HU-210 reduce the development of
precancerous lesions in the mouse colon [26]. These and
our data suggest that the endocannabinoid system has a
physiological protective role against tumorigenesis, in
line with the general idea that this system contributes to
maintain homeostasis in health and disease [6].
Data presented herein show that cannabinoids modu-
late MMP activity. In particular, we report an inhibition
of MMP2 and an activation of MMP9 by cannabinoids.
Although MMPs have been traditionally associated to
metastasis due to their ability to degrade the extracellu-
lar matrix, it has been recently shown that several mem-
bers of this family provide a protective effect in different
stages of cancer progression [27]. One of these antitu-
moral MMPs is MMP9, which is activated by cannabi-
noids in our system. Although this MMP may promote
the angiogenic switch in some experimental tumors [e.g.
[28]], clinical studies have established a correlation
between MMP9 overexpression and good prognosis in
breast cancer [29]. This protective effect might derive
from its capacity to generate angiogenesis inhibitors
such as angiostatin and tumstatin [27]. The inhibition of
MMP2 by cannabinoids shown here, in line with that
previously reported by Bifulco and coworkers in thyroid
cancer cells [30] and our group in gliomas [31], may be
of special relevance considering that high tumor levels
of this metalloproteinase have been correlated with poor
prognosis in breast cancer [32]. In addition, enhanced
levels of MMP2 in breast tumors are associated with
ErbB2 gene amplification and/or overexpression [33].
Moreover, Massagué and coworkers have recently iden-
tified MMP2 as one of the genes of the signature that
mediates breast cancer metastasis to the lungs [34], the
targeted metastatic organ in our animal model.
Potential antitumoral therapies based on the use of
cannabinoids might be limited by their well known psy-
chotropic actions such as dizziness, dry mouth, tired-
ness, muscle weakness, euphoria, myalgia and
palpitations [6,35]. Although the benefit/risk ratio is
potentially high for cannabinoid-based therapies, differ-
ent strategies should be taken to avoid or at least mini-
mize their side effects. Since most -if not all- of the
psychoactive effects of cannabinoids are produced by
the activation of central CB1 receptors [5,6], one reason-
able approach would be targeting CB2 receptors
selectively. Here, we have demonstrated that the CB2-
selective agonist JWH-133 is as effective as THC (a
CB1/CB2-mixed agonist) in reducing tumor generation
and progression. Moreover, our results also (i) show
that an elevated percentage of high grade ErbB2-positive
human breast tumors express CB2 receptors, and (ii)
that a very low fraction of them express CB1 receptors.
Taken together, these data suggest that activation of
CB2 in this particular population of patients would be
an efficient strategy to treat breast tumors without trig-
gering psychoactive effects. A correlation between
tumor aggressiveness and CB2 receptor expression in
breast cancer has been previously reported: tumors lack-
ing estrogen or progesterone receptors, which are asso-
ciated to low response rates to adjuvant therapies,
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express higher CB2 levels than steroid receptor-positive
lesions [17]. Moreover, ErbB2-positive tumors also have
increased CB2 receptor mRNA levels compared to their
less aggressive and more responsive ErbB2-negative
counterparts [17]. Of interest, this receptor is scarcely
expressed in non-transformed mammary tissue [data
presented here and [17,21]].
Conclusions
In summary, our results, which were obtained in a clini-
cally relevant animal model of ErbB2-positive breast
cancer, suggest that these highly aggressive and low
responsive tumors could be efficiently treated with non-
psychoactive CB2-selective agonists without affecting the
surrounding healthy tissue.
Methods
Tissue microarray analysis
Eighty seven grade 3 invasive breast ductal carcinomas
and 6 non-tumoral mammary tissues were fixed in 10%
paraformaldehide (PFA) and embedded in paraffin.
Two representative tissue cores (1 mm of diameter) of
each one were included in a tissue microarray. The
main clinical pathology and molecular features of this
series had been previously reported [36]. Tissue sec-
tions were subjected to a heat-induced antigen retrieval
step prior to exposure to the primary antibody. Anti-
CB1 receptor antibody was generously donated by Dr.
Ken Mackie, Indiana University, Indiana, and anti-CB2
receptor antibody was from Affinity Bioreagents/
Thermo Fisher Scientific, Rockford, Illinois. ErbB2
expression was evaluated using a HercepTest (Dako,
Carpenteria, CA) according to manufacturer’s instruc-
tions. Immunodetection was performed using the
LSAB method (DAKO) with DAB as the chromogen.
In negative controls, the primary antibody was omitted
or replaced with an irrelevant antibody. Cases were
reviewed by two independent pathologists (J.P. and
G.M-B) and were scored as positive for cannabinoid
receptors when more than 25% of the neoplastic cell
showed intense immunostaining for the corresponding
antibody. ErbB2-staining was scored according to Her-
cepTest manufacturer’s guidelines: scores 0 and 1+
were considered as negative, and 2+ and 3+ as positive
for ErbB2 overexpression.
Animals and treatments
All procedures involving animals were performed with
the approval of the Complutense University Animal
Experimentation Committee according to the European
official regulations. FVB/N-Tg(MMTVneu)202 Mul/J
mice (more commonly designated as MMTV-neu mice)
were obtained from The Jackson Laboratory (Bar Har-
bor, Maine). Females were palpated twice weekly for
mammary gland nodules and cannabinoid treatment
was started when the first tumor in each animal was
detected. Δ9-Tetrahydrocannabinol (THC, The Health
Concept, Richelbach, Germany) and JWH-133 (kindly
donated by John W. Huffman, Clemson University,
South Carolina) were prepared in DMSO (0.2 mg/μL
and 0.02 mg/μL, respectively) and diluted in PBS sup-
plemented with 5% BSA (100 μL/dose for tumors ≤
1000 mm3 and 200 μl/dose for tumors >1000 mm3).
Cannabinoid peritumoral treatment (0.5 mg THC or
0.05 mg JWH-133/animal/day, twice a week) was main-
tained for 90 days, and only the first tumor in each ani-
mal was treated. Tumors were routinely measured
during this period with external caliper, and volume was
calculated as (4π/3) × (width/2)2 × (length/2). At the
end of the treatment, animals were sacrificed and
tumors and organs were collected. Tumors were divided
in four portions for 1) preparation of tissue sections for
immunofluorescent staining [frozen in Tissue-Tek
(Sakura Finetek Europe, Zoeterwoude, The Nether-
lands)], 2) preparation of tissue sections for hematoxy-
lin-eosin staining (fixed in buffered 4% PFA), 3) protein
extraction (snap frozen) and 4) RNA isolation (snap fro-
zen), and were stored at -80°C until analysis (except
PFA-fixed tumor fractions, that were kept at room tem-
perature). Brain, spleen, liver, kidneys and lungs were
fixed in PFA. For xenograft experiments, subcutaneous
tumors were induced in 6 week-old athymic female
mice (Harlan Interfauna Iberica, Barcelona, Spain) by
subcutaneous injection of 5 × 105 N202.1A cells. When
tumors reached ca. 100 mm3, they were treated with
THC (0.5 mg/animal/day), JWH-133 (50 μg/animal/day),
SR144528 (50 μg/animal/day), a combination of canna-
binoid and SR144528 or vehicle for 3 weeks, 3 times a
week, measured, and processed as described above. For
Akt-related experiments, half of the animals were
injected with N202.1A cells stably expressing myristoy-
lated Akt (N202.1A-pBABE-myr-Akt), and the other
half with N202.1A cells stably expressing the corre-
sponding empty vector (N202.1A-pBABE). Tumors were
treated with THC, JWH-133 or vehicle and processed as
described for N202.1A xenografts.
Metastasis detection
Collected organs were visually analyzed for macroscopic
metastases. Microscopic metastases were determined by
histological analysis of PFA-fixed paraffin-embedded
hematoxylin-eosin stained sections. Radiographs were
taken to evaluate the presence of bone metastases using
a conventional X-ray equipment (Diagnost 93, Philips
Medical Systems, Eindhoven, The Netherlands), and
mammography cassette (Kodak MIN-R 2000 screen cas-
sette) and film (Kodak MIN-R S film) (Eastman Kodak
Company, Rochester, New York).
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Cell culture and viability
N202.1A cells were kindly given by Dr. Vincenzo Bronte
(Istituto Oncologico Veneto, Padova, Italy). This cell
line was established from a MMTV-neu-derived tumor
[13]. BT474, MDA-MB-231, MCF-7 and SkBr3 human
breast cancer cells, Jurkat human leukemic cells, and
U373 human glioblastoma cells were from ATCC-LGC
(Barcelona, Spain). All cell lines were maintained in
DMEM supplemented with 10% fetal bovine serum
(FBS). Cells were transferred to a low (0.5%)-FBS med-
ium immediately before cannabinoid challenge. Cell via-
bility was determined by the 3-4,5-dimethylthiazol-2,5-
diphenyltetrazolium bromide thiazol blue test (Sigma,
St. Louis, Missouri) according to manufacturer’s
instructions.
Plasmids, transfections and infections
Stable expression of myr-Akt was achieved by retroviral
infection. N202.1A cells were transduced for 4 h with
supernatants obtained from Phoenix ecotropic cells pre-
viously transfected with a retroviral vector carrying HA-
tagged myr-Akt (kindly provided by Dr. Pier P. Pandolfi,
Harvard University, Boston, Massachusetts) or the cor-
responding empty construction (pBABE). Infected cells
were selected with puromycin.
Immunofluorescence analysis
Tissue-tek embedded tumor sections were fixed in PFA
and incubated with anti-CB1 receptor, anti-CB2 receptor,
anti-CD31 (Pharmingen/BD Biosciences, San Jose, Cali-
fornia), anti-CD45 (Pharmingen/BD Biosciences), anti-
Ki67 (Neomarkers/Lab Vision, Fremont, California) or
anti-cleaved-caspase 3 (Cell Signaling Technology, Dan-
vers, Massachusetts) antibodies. Secondary anti-rabbit
antibodies AlexaFluor 594 and AlexaFluor 488 were
from Invitrogen (Carlsbad, California). Cell nuclei were
stained with Hoescht 33342 (Invitrogen). Fluorescence
images were acquired using Metamorph Premier Offline
software (Molecular Devices, Sunnyvale, California).
Blood vessel size was calculated with ImageJ software.
Real-time quantitative PCR (RTQ-PCR) and reverse-
transcriptase PCR (RT-PCR)
RNA was isolated with Trizol Reagent (Invitrogen),
including a DNase digestion step, with the Real Star Kit
(Durviz, Valencia, Spain), and cDNA was obtained with
Transcriptor Reverse Transcriptase (Roche Applied
Science, Penzberg, Germany). The primers used for
RTQ-PCR amplification were: mouse CB1 receptor,
sense 5′-GGGCAAATTTCCTTGTAGCA-3′, antisense
5′-GGCTCAACGTGACTGAGAAA-3′; mouse CB2
receptor, sense 5′-ATTCAGGAGATCTGTTAAGA
CAAGG-3′, antisense 5′-GACATCTATGAAGTTGAG
GCAGTG-3′; mouse MMP2, sense 5′- GCGCTTTTC-
TCGAATCCAT-3′, antisense 5′-GGGTATCCATCTC
CATGCTC-3′; mouse MMP9, sense 5′-ACGACATA
GACGGCATCCA-3′, antisense 5′- GCTGTGGTTCA
-GTTGTGGTG-3′; rat ErbB2 (neu), sense 5′-GCTCA
GAGACCTGCTTTGGA-3′, antisense 5′-AGGAGGAC
GAGTCCTTGTAGTG-3′; mouse ErbB2, sense 5′-
AACAGCTCGGAGACCTGCTA-3′, antisense 5′-
GTAGTGGGCACAAGCCTCA-3′. Probes were from
the Universal Probe Library (Roche Applied Science).
Multispecies 18S RNA was used as reference (sense 5′-
GCTCTAGAATTACCACAGTTATCCAA-3′, antisense
5′- AAATCAGTTATGGTTCCTTTGGTC-3′). The pri-
mers use for RT-PCR were: mouse MMP2, sense 5′-
TCTGCGATGAGCTTAGGGAAAC-3′, antisense 5′-
GACATACATCTTTGCAGGAGACAAG-3′; mouse
MMP9, sense 5′-GGACGACGTGGGCTACGT-3′,
antisense 5′- CACGGTTGAAGCAAAGAAGGA-3′.
GAPDH was used as reference (sense 5′-GGGAAGCT
CACTGGCATGGCCTTCC-3′, antisense 5′-CATGTG
GGCCATGAGGTCCACCAC-3′).
Western blot analysis
Cell lysates from tumors and cell lines were subjected to
SDS-PAGE, and proteins transferred onto polyvinylidene
fluoride membranes. Blots were incubated with the fol-
lowing antibodiess: anti-CB1 receptor, anti-CB2 receptor
(Affinity Bioreagents), anti-MMP9 (Chemicon Interna-
tional INC, Temecula, California), anti-ErbB2 (Santa
Cruz Biotechnology, Santa Cruz, California), anti-phos-
pho-Akt (Ser473), anti-Akt, anti-phospho-S6 ribosomal
protein (Cell Signaling) and anti-a-tubulin (Sigma).
Luminograms were obtained with the Amersham
Enhanced Chemiluminescence Detection Kit (GE
Healthcare, Uppsala, Sweden) and densitometric analysis
was performed with Quantity One software (Bio-Rad).
MMP activity assay
MMP2 (Gelatinase A) and MMP9 (Gelatinase B) activ-
ities were determined by gelatin zymography. Briefly,
SDS-PAGE were run in the presence of 0.1% gelatin,
washed with a 2.5% Triton X-100 containing buffer, and
incubated overnight at 37°C in 50 mM Tris pH 7.5, 150
mM NaCl, 10 mM CaCl2, 0.1% Triton X100. Gels were
then stained with Coomasie Blue and digested bands
quantified by densitometric analysis as described above.
Statistical analysis
ANOVA with a post hoc analysis by the Student-New-
man-Keuls’ test was routinely used. For the analysis of
metastases and the number of tumors per animal, a
Pearson Х2 test was used. To determine the correlation
between immunohistochemical (CB1 and CB2 expres-
sion) and clinical pathology (ErbB2) data, the Х2 test
with Yates correction, or Fisher’s exact test, was used.
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The SPSS for Windows program (SPSS, Inc., Chicago,
IL, version 17.0) was used for this analysis. All P-values
were two-sided. Unless otherwise stated, data are
expressed as mean ± s.e.m.
Additional material
Additional file 1: Figures S1-S5. Supplemental Figure 1: MMTV-neu
mice spontaneously develop breast tumors and lung metastases.
Supplemental Figure 2: Cannabinoids inhibit breast tumor growth in vivo
Supplemental Figure 3: MMTV-neu-derived tumors express cannabinoid
receptors Supplemental Figure 4: Cannabinoids modulate the expression
of MMP2 and MMP9 Supplemental Figure 5: Human ErbB2-positive
breast cancer cell lines are sensitive to cannabinoids
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